Srinivas Akkaraju Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 1 month, 2 weeks ago
Srinivas Akkaraju has an estimated net worth of at least $15.8 million*, as of Oct. 29, 2025. They own 521,571 shares of SRRK stock. They have sold 1.2 million shares of SRRK stock since 2021, for an estimated $578,320.
Srinivas Akkaraju $SRRK SEC Form 4 Insider Trading
Srinivas Akkaraju has filed a total of 10 insider trades in $SRRK since 2021. Their most recent trade was a purchase of 11,011 shares, made on Oct 03, 2025. Their largest trade was a purchase of 2.2 million shares, made on Oct 16, 2023. We estimate that they now own 521,571 shares of $SRRK, worth an estimated $15.2 million.
Insider Trading at $SRRK
There have been a total of 123 insider trades reported at $SRRK since 2021, with 8.6 million shares purchased and 4.4 million shares sold. The most active insider traders in $SRRK stock have been Edward H Myles, Mo Qatanani, and Jing L. Marantz. The most recent trade was a sale of 136,462 shares reported by Mo Qatanani (CHIEF SCIENTIFIC OFFICER), made on Dec 04, 2025.
History of Insider Stock Trades by Srinivas Akkaraju
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
ALMS
|
Purchase | 64,969 | Dec 05, 2025 | Dec. 9, 2025, 8:13 p.m. |
ALMS
|
Purchase | 70,028 | Dec 05, 2025 | Dec. 9, 2025, 8:13 p.m. |
ALMS
|
Purchase | 51,380 | Dec 05, 2025 | Dec. 9, 2025, 8:13 p.m. |
ALMS
|
Purchase | 66,027 | Dec 04, 2025 | Dec. 4, 2025, 9:11 p.m. |
ALMS
|
Purchase | 96,000 | Dec 02, 2025 | Dec. 4, 2025, 9:11 p.m. |
ALMS
|
Purchase | 100,000 | Dec 03, 2025 | Dec. 4, 2025, 9:11 p.m. |
ALMS
|
Purchase | 86,350 | Dec 01, 2025 | Dec. 3, 2025, 10:06 p.m. |
ALMS
|
Purchase | 48,537 | Nov 26, 2025 | Dec. 3, 2025, 10:06 p.m. |
ALMS
|
Purchase | 38,702 | Nov 28, 2025 | Dec. 3, 2025, 10:06 p.m. |
ALMS
|
Purchase | 125,743 | Nov 20, 2025 | Nov. 24, 2025, 7:50 p.m. |
ALMS
|
Purchase | 914 | Nov 17, 2025 | Nov. 19, 2025, 9:46 p.m. |
ALMS
|
Purchase | 102,652 | Nov 18, 2025 | Nov. 19, 2025, 9:46 p.m. |
ALMS
|
Purchase | 137,772 | Nov 19, 2025 | Nov. 19, 2025, 9:46 p.m. |
ALMS
|
Purchase | 276,179 | Nov 13, 2025 | Nov. 17, 2025, 5:59 p.m. |
SRRK
|
Purchase | 11,011 | Oct 03, 2025 | Oct. 7, 2025, 8:59 p.m. |
SRRK
|
Purchase | 319,700 | Oct 03, 2025 | Oct. 7, 2025, 8:59 p.m. |
SRRK
|
Purchase | 18,414 | Oct 06, 2025 | Oct. 7, 2025, 8:59 p.m. |
SRRK
|
Purchase | 80,863 | Oct 06, 2025 | Oct. 7, 2025, 8:59 p.m. |
SRRK
|
Purchase | 13,748 | Oct 06, 2025 | Oct. 7, 2025, 8:59 p.m. |
SRRK
|
Purchase | 56,703 | Oct 03, 2025 | Oct. 7, 2025, 8:59 p.m. |
MLYS
|
Purchase | 588,235 | Sep 04, 2025 | Sept. 8, 2025, 8:07 p.m. |
ALMS
|
Purchase | 138,368 | May 05, 2025 | May 6, 2025, 6:52 p.m. |
ALMS
|
Purchase | 22,002 | May 05, 2025 | May 6, 2025, 6:52 p.m. |
ALMS
|
Purchase | 159,920 | May 02, 2025 | May 6, 2025, 6:52 p.m. |
MLYS
|
Purchase | 600,000 | Mar 13, 2025 | March 17, 2025, 9:04 p.m. |
SRRK
|
Sale | 510,000 | Oct 07, 2024 | Oct. 7, 2024, 8:55 p.m. |
SRRK
|
Sale | 510,000 | Oct 07, 2024 | Oct. 7, 2024, 8:55 p.m. |
SRRK
|
Sale | 155,713 | Oct 07, 2024 | Oct. 7, 2024, 8:55 p.m. |
SYRS
|
Purchase | 904,977 | Dec 21, 2023 | Dec. 26, 2023, 6:24 p.m. |
SRRK
|
Purchase | 2.2 million | Oct 16, 2023 | Oct. 18, 2023, 5:46 p.m. |
MLYS
|
Purchase | 937,500 | Feb 14, 2023 | Feb. 16, 2023, 5:54 p.m. |
KDNY
|
Purchase | 570,000 | May 27, 2022 | June 1, 2022, 4:13 p.m. |
KDNY
|
Purchase | 1.2 million | Nov 15, 2021 | Nov. 17, 2021, 1:05 p.m. |
KDNY
|
Purchase | 208,500 | Aug 18, 2021 | Aug. 19, 2021, 8 p.m. |
GRPH
|
Purchase | 15,000 | Jun 29, 2021 | June 30, 2021, 8 p.m. |
GRPH
|
Purchase | 485,000 | Jun 29, 2021 | June 30, 2021, 8 p.m. |
$SRRK Executives and Stock Owners with Insider Trades
-
Edward H Myles, COO & CFO
-
Mo Qatanani, CHIEF SCIENTIFIC OFFICER
-
Jing L. Marantz, CHIEF MEDICAL OFFICER
-
Caryn Parlavecchio, CHRO
-
Junlin Ho, GENERAL COUNSEL
-
Tracey Sacco, Chief Commercial Officer
-
Edward H Myles, Chief Financial Officer
-
Jay T. Backstrom, CHIEF EXECUTIVE OFFICER
-
Mo Qatanani, SVP AND HEAD OF RESEARCH
-
Akshay Vaishnaw, President of R&D
-
Tracey Sacco, CHIEF COMMERCIAL OFFICER
-
Erin Moore, Interim PFO and PAO
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.